Pirfenidone trials complete recruitment ahead of schedule

California, USA-based drugmaker InterMune says that it has completed patient enrollment in two Phase III trials evaluating pirfenidone as a treatment for patients with idiopathic pulmonary fibrosis. The firm added that the program, known as CAPACITY, is seven months ahead of schedule and has recruited 194 more participants than originally planned.

CAPACITY is designed to evaluate the safety and tolerability of the drug in IPF sufferers with mild-to-moderate impairment in lung function. The primary endpoint of both studies is an improvement in lung function, as measured by a change in forced vital capacity. The firm expects top-line results to be available in late-2008.